JP2007512347A5 - - Google Patents

Download PDF

Info

Publication number
JP2007512347A5
JP2007512347A5 JP2006541438A JP2006541438A JP2007512347A5 JP 2007512347 A5 JP2007512347 A5 JP 2007512347A5 JP 2006541438 A JP2006541438 A JP 2006541438A JP 2006541438 A JP2006541438 A JP 2006541438A JP 2007512347 A5 JP2007512347 A5 JP 2007512347A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
hmg
composition according
coa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006541438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/039657 external-priority patent/WO2005053683A1/en
Publication of JP2007512347A publication Critical patent/JP2007512347A/ja
Publication of JP2007512347A5 publication Critical patent/JP2007512347A5/ja
Pending legal-status Critical Current

Links

JP2006541438A 2003-11-26 2004-11-26 緑内障を予防するかまたは治療する方法 Pending JP2007512347A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52491203P 2003-11-26 2003-11-26
PCT/US2004/039657 WO2005053683A1 (en) 2003-11-26 2004-11-26 A method of preventing or treating glaucoma

Publications (2)

Publication Number Publication Date
JP2007512347A JP2007512347A (ja) 2007-05-17
JP2007512347A5 true JP2007512347A5 (cg-RX-API-DMAC7.html) 2008-01-17

Family

ID=34652282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541438A Pending JP2007512347A (ja) 2003-11-26 2004-11-26 緑内障を予防するかまたは治療する方法

Country Status (4)

Country Link
US (1) US8415364B2 (cg-RX-API-DMAC7.html)
EP (1) EP1722780A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007512347A (cg-RX-API-DMAC7.html)
WO (1) WO2005053683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
WO2005105069A1 (en) * 2004-04-26 2005-11-10 Alcon, Inc. Statins for the treatment of ocular hypertension and glaucoma
WO2006047466A2 (en) * 2004-10-21 2006-05-04 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
PL2018153T3 (pl) 2006-04-26 2012-09-28 Rosemont Pharmaceuticals Ltd Ciekłe kompozycje doustne
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10493274B2 (en) 2013-12-09 2019-12-03 Purdue Research Foundation Optical pressure treatment through electrical stimulation
JP7482024B2 (ja) 2017-08-04 2024-05-13 パーデュー リサーチ ファウンデーション 無線緑内障治療のためのマルチコイル無線電力伝送アセンブリ
US11191962B2 (en) 2018-03-12 2021-12-07 Purdue Research Foundation Stimulus coil and pulse generator for wireless glaucoma therapy
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
WO2025080770A1 (en) * 2023-10-10 2025-04-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ocular applications of combination therapy using statins and matrix bound vesicles (mbvs)

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (cg-RX-API-DMAC7.html) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5041450A (en) 1988-06-29 1991-08-20 Research Corporation Technologies, Inc. Treatment of ocular inflammation
IL91941A (en) 1988-10-13 1994-10-21 Sandoz Ag Preparation of 6-Anoic and 7-Metanoic Fatty Acids and Their Substances and Intermediate Compounds and Acid 7-] 3-) 4-Fluorophenyl (-1-) 1- Methylethyl (a)
FR2647675B1 (fr) * 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
AU3064892A (en) 1991-11-07 1993-06-07 University Of Southern California Compositions and methods for preventing adhesion formation
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
JP2800877B2 (ja) * 1993-12-28 1998-09-21 伊藤ハム株式会社 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0738510A3 (fr) 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
CA2227265C (en) 1995-08-14 2012-01-03 The Scripps Research Institute Methods and compositions useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
JPH1017488A (ja) 1996-06-25 1998-01-20 Asahi Glass Co Ltd 緑内障治療薬
US5900414A (en) 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
KR100616466B1 (ko) 1998-08-17 2006-08-29 센주 세이야꾸 가부시키가이샤 녹내장 예방/치료제
JP2000336042A (ja) * 1999-03-25 2000-12-05 Santen Pharmaceut Co Ltd 眼圧下降剤
EP1258253A1 (en) 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
SE0002354D0 (sv) 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
EP1298223A3 (en) 2001-09-28 2003-07-23 Pfizer Products Inc. Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
JP4300347B2 (ja) * 2002-01-29 2009-07-22 参天製薬株式会社 ブナゾシンとプロスタグランジン類からなる緑内障治療剤
ATE336247T1 (de) 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
PE20040291A1 (es) * 2002-03-22 2004-07-02 Novartis Ag COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
US20030195167A1 (en) 2002-04-15 2003-10-16 Kowa Co., Ltd. PTX3-gene expression inhibitor
JP2004149480A (ja) 2002-10-31 2004-05-27 Saisentan Igaku Kenkyusho:Kk 経口又は経皮投与用の眼科疾患治療剤
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
WO2005105069A1 (en) 2004-04-26 2005-11-10 Alcon, Inc. Statins for the treatment of ocular hypertension and glaucoma
WO2005105155A1 (en) 2004-04-28 2005-11-10 Saitama Medical School Methods for delivering a gene product to the eye

Similar Documents

Publication Publication Date Title
Corsini et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins
CA2536187C (en) Pharmaceutical composition comprising a combination of metformin and a statin
JP2002501887A5 (ja) アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用
WO2001068096A2 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20110098314A1 (en) Statins for the treatment of ocular hypertension and glaucoma
US20150272944A1 (en) Novel triglyceride reducing agent
US20100240683A1 (en) Combination therapy, composition and methods for the treatment of cardiovascular disorders
JP2002508320A5 (cg-RX-API-DMAC7.html)
JP2005200419A5 (cg-RX-API-DMAC7.html)
RU2007149337A (ru) Новый способ лечения гиперлипидемии
JP2003524582A5 (cg-RX-API-DMAC7.html)
WO2005058310A3 (en) Use of stating for the treatment of metabolic syndrome
JP2002506818A5 (cg-RX-API-DMAC7.html)
JP2008513379A5 (cg-RX-API-DMAC7.html)
RU2006114579A (ru) Комбинации ингибитора биосинтеза холестерина и растворимого волокна для лечения состояний, связанных с повышенным содержанием холестерина
RU2007148908A (ru) Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
CA2798707A1 (en) Association of xanthine oxidase inhibitors and statins and use thereof
CN1473042A (zh) 药物组合物
US20050182106A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
CN1481240A (zh) 抗血脂剂
RU2380360C2 (ru) Дифенилазетидиноновые производные, обладающие активностью, ингибирующей всасывание холестерина
HK1111632B (en) Novel triglyceride reducing agent
CO5611117A2 (es) Combinacion de compuestos organicos